- AimedBio’s novel brain tumor therapeutics, AMB302, was selected as a government-initiated drug development program
by the Korean Drug Development Fund (KDDF).
- ‘AMB302’
is a first-in-class ADC therapeutics targeting a brain tumor specific fusion
oncogene.
- AimedBio
has confirmed significant tumor killing effect of ‘AMB302’ candidate.
- AimedBio utilizes patients’ genetic/clinical data and patient-derived samples in the antibody development process,
resulting in higher probability of clinical success.